Skip to content
Search

Latest Stories

Pharmacy First: Imaan Healthcare calls for fair reimbursement, lower target

Imaan Healthcare pharmacies conducted over 32,000 Pharmacy First consultations in past one year
Need to reassess Pharmacy First reimbursement levels (gettyimages)

The time taken to provide Pharmacy First warrants more than £15 per delivery of service – says Saghir Ahmed

The launch of Pharmacy First last year marked a significant milestone for the community pharmacy sector, but the journey has been far from easy.

Pharmacy teams have had to struggle with IT glitches, a weak NHS marketing campaign, and low GP referral rates, combined with ongoing financial and operational pressures, making it difficult for many to meet the monthly payment thresholds.


Despite facing numerous challenges, Imaan Healthcare have successfully conducted over 32,000 Pharmacy First consultations across their network since the service started.

Saghir Ahmed, director of operations & development at Green Life Pharma and Imaan Healthcare, told Pharmacy Business that nearly all of their 70 community pharmacies have consistently achieved the clinical pathways thresholds each month.

However, he cautioned that the current target of 30 consultations per month may become “unachievable” in a few months as the conditions covered are very winter-centric, stressing the need to reduce the monthly thresholds.

When asked what support or improvements are needed to enhance the service, he emphasised the importance of GP engagement, stating, “GPs need to support the delivery of the service and realise that this helps them.”

“We also need more pathways developed for other conditions.”

Ahmed highlighted that pharmacists have been able to deliver the service effectively as “the PGDs and pathways are well designed by NHS England.”

He emphasised that pharmacists should now be with further expansion of the service.

Furthermore, Ahmed stressed the need to reassess reimbursement levels.

“Pharmacists will never refuse to see a patient, but the time taken to provide the service warrants more than £15 per delivery of service.

“Furthermore, this fee is only applicable if the patient meets gateway criteria, and pharmacists are seeing patients who do not meet gateway criteria but still finding ways to treat them. They need to be reimbursed for their time and expertise.”

What key recommendations to policymakers for improving the Pharmacy First scheme moving forward?

When asked about key recommendations for improving the Pharmacy First scheme, Ahmed stated, “Expand the service and reimburse at an adequate and fair rate.”

Need financial stabilisation before service expansion

Since its launch on 31st January 2024, nearly 98 per cent of community pharmacies have registered to provide the Pharmacy First service.

According to Community Pharmacy England (CPE), almost two million Pharmacy First consultations have now been delivered over the past 12 months.

The Committee has been advocating for the expansion of Pharmacy First, with proposals to introduce additional clinical pathways and incorporate independent prescribing within the service. These recommendations were key elements of its submission to the NHS 10-Year Health Plan.

However, the Committee emphasised that such developments would only be achievable if the government and NHS first commit to “financial stabilisation of the sector.”

For further developing Pharmacy First, it recommends launching a much bigger, ongoing public awareness campaign; implementing measures to boost referral rates from GP practices and NHS 111; and expanding the walk-in element to all parts of the service.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less